Theodore D Dumont Ruel

Dr. Theodore D Dumont Ruel

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in The Lancet HIV
Verified
Journal Article
Open access
TRTheodore D Dumont Ruel
Theodore D Dumont Ruel
EAEdward P Acosta
Edward P Acosta
JLJessica P Liu
Jessica P Liu
KGKathryn P Gray
Kathryn P Gray
KGKathleen George
Kathleen George
IGIvete Martins Gomes
Ivete Martins Gomes
Safe and potent antiretroviral medications in child-friendly formulations are needed to treat young children living with HIV-1 The primary objective of this study was to select dosing for a dispersible tablet formulation of dolutegravir that achieved pharmacokinetic exposures similar to those in adults, and was safe and well-tolerated in young children. IMPAACT P1093 is a Phase I/II ongoing multi-centre, open-label, non-comparative study of dolutegravir treated with 5mg dispersible tablet formulation. Children 4 weeks to < 6 years old, weighing ≥ 3kg, with HIV RNA > 1000 copies/mL and no prior integrase-strand-transfer-inhibitor treatment were recruited in Africa, Asia and the Americas from 2017 to 2020. Doses were selected based on intensive pharmacokinetic evaluation on day 5–10, with safety and tolerability assessed through 48 weeks. The analysis included 73 (48% female) participants with median (range) age of 1 (0·1, 6·0) years, weight of 8·5 (3·7, 18·5) kg, plasma HIV-1 RNA level of 4·2 (2·1, 7·0) (log10 copies/mL), and CD4% was 24·0 (0·3, 49·0); 64 (87·7%) were treatment-experienced. The selected dose within each age cohort (≥ 2 to < 6 years, ≥ 6 months to < 2 years of age and ≥ 4 weeks to < 6 months) achieved geometric mean trough (ng/mL) of 688, 1179, and 1446, and 24-hour area-under-the-curve (hr*mg/L) of 53, 74, and 65, respectively. No grade 3 or worse adverse events were attributed to dolutegravir. Dispersible tablet palatability was rated as good or better in 97% of reports from 73 responders. In this study, the proposed once-daily dosing of dolutegravir dispersible tablets provided drug exposures comparable to adults, and was safe and well-tolerated. These data support the use of dolutegravir dispersible tablets as first- or second-line treatment for infants and children < 6 years old with HIV-1. This trial is registered at ClinicalTrials.gov (NCT01302847)

5 April 2019 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
RVRolando M Viani
Rolando M Viani
TRTheodore D Dumont Ruel
Theodore D Dumont Ruel
CACarmelita Alvero
Carmelita Alvero
TFTerry Fenton
Terry Fenton
EAEdward P Acosta
Edward P Acosta
CKCatherine Kneut
Catherine Kneut
Background: P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy outcomes for the oldest cohort. Methods: The study enrolled human immunodeficiency virus type 1 (HIV-1)–infected treatment-experienced adolescents aged 12 to <18 years, with an HIV-1 RNA level ≥1000 copies/mL . Cumulative safety and HIV-1 RNA outcomes were assessed once the last enrolled participant reached 144 weeks of follow-up. Results: Among 23 adolescents enrolled, 16 remained in the study at least 144 weeks; the median follow-up was 153 weeks (range, 55–193 weeks). Dolutegravir was well tolerated, with grade 3 clinical adverse events in 5 participants, grade 3 laboratory abnormalities in 3, and grade 4 laboratory abnormalities in 1; none of the adverse events or abnormalities were judged to be treatment related. In an-intent-to-treat analysis, an HIV-1 RNA level <400 copies/mL at week 144 was achieved in 43% (10 of 23 participants; 95% confidence interval, 23.2%–65.5%); in addition, 35% (8 of 23; 16.4%–57.3%) had an HIV-1 RNA level <50 copies/mL. Nine participants (39%) discontinued study treatment before 144 weeks, but none because of adverse events or drug intolerance. All participants with sustained virologic control had excellent adherence; most who experienced virologic failure had adherence levels <90%. HIV-1 genotypic drug resistance testing was available at time of failure from 6 participants; 1 had evolution in integrase resistance with E138T, S147G, and R263K mutations at week 192 and phenotypic dolutegravir resistance of a 5.1-fold change. Conclusions: Dolutegravir plus an optimized background regimen seemed safe, well tolerated, and efficacious in this cohort of treatment-experienced HIV-1-infected adolescents. Adherence remains problematic in this population. Clinical Trials Registration: NCT01302847.

31 March 2023 in Global Health: Science and Practice
Verified
Journal Article
Open access
PDF file
TRTheodore D Dumont Ruel
Theodore D Dumont Ruel
MPMartina Penazzato
Martina Penazzato
JZJennifer M. Zech
Jennifer M. Zech
MAMoherndran Archary
Moherndran Archary
TCTim R. Cressey
Tim R. Cressey
EAElaine J. Abrams
Elaine J. Abrams
Key Messages Postnatal prophylaxis continues to play an essential role in efforts to eliminate new pediatric HIV infections and maximize HIV-free survival. New approaches to postnatal prophylaxis using currently available modern oral antiretroviral drugs could surmount many current barriers. Long-acting agents and delivery platforms currently in development for treating people living with HIV have great potential as postnatal prophylaxis for infants. Studies of novel postnatal prophylactic agents are possible and imperative in the near future and must be prioritized early in the antiretroviral drug development pipeline. Close collaboration between researchers, community representatives, industry, regulators, and policymakers will be the critical ingredient to ensure HIV-free survival for all infants with HIV exposure.

19 February 2021 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
MMMary Muhindo
Mary Muhindo
JBJoshua Bress
Joshua Bress
RKRogers Kalanda
Rogers Kalanda
JAJean Armas
Jean Armas
EDElon Danziger
Elon Danziger
TRTheodore D Dumont Ruel
Theodore D Dumont Ruel
Background: Lack of trained health care workers and nonadherence to national guidelines are key barriers to achieving high-quality newborn care in health care facilities in low- and middle-income countries. Traditional didactic approaches addressing these barriers fail to account for high staff turnover rates and result in temporary behavior change. NoviGuide, a clinical decision support software designed to standardize neonatal care through point-of-care assessments, has the potential to align bedside practice to national guidelines in settings lacking subspecialty neonatal providers. Objective: This study aims to determine the adaptation, adoption, feasibility, acceptability, and sustainability of NoviGuide and its impact on nurse-midwives’ knowledge in a rural hospital in eastern Uganda. Methods: This mixed methods observational study was guided by the Proctor framework. Experts reviewed the clinical content of NoviGuide to ensure fidelity to Uganda guidelines. We enrolled nurses and midwives providing newborn care at Tororo District Hospital, trained them on NoviGuide use, and followed them for 12 months. We assessed adoption, feasibility, acceptability, and sustainability by analyzing NoviGuide use data, comparing it with maternity registry data and administering the System Usability Scale (SUS) and the Center for Health Care Evaluation Provider Satisfaction Questionnaire. We compared the mean knowledge assessment score at baseline, 6 months, and 12 months using a two-tailed t test. Results: Five Ugandan experts suggested two minor changes to NoviGuide: the inclusion of an unsterile birth environment as an indication for empiric antibiotics and the addition of a reminder to follow-up with newborns with temperatures between 37.7°C and 37.9°C. Of the 19 nurse-midwives enrolled in February 2017, 74% (n=14) completed the follow-up in March 2018. The participants entered a total of 1705 assessments of varying newborn characteristics into NoviGuide throughout the day, evening, and night nursing shifts. The SUS score at the end of the study was very high (93.5, above the average of 68). Participants had a positive perception about NoviGuide, reporting that NoviGuide saved time (mean 5, SD 0) and prevented mistakes (mean 5, SD 0), and that they felt more confident in taking care of newborns when they used NoviGuide (mean 5, SD 0). Participants were highly satisfied with NoviGuide (mean 4.86, SD 0.36), although they lacked medical supplies and materials needed to follow NoviGuide recommendations (mean 3.3, SD 1.22). The participants’ knowledge scores improved by a mean change of 3.7 (95% CI 2.6-4.8) at 6 months and 6.7 (95% CI 4.6-8.2) at 12 months (P<.001). Conclusions: NoviGuide was easily adapted to the Uganda guidelines. Nurse-midwives used NoviGuide frequently and reported high levels of satisfaction despite challenges with medical supplies and high staff turnover. NoviGuide improved knowledge and confidence in newborn care without in-person didactic training. NoviGuide use has the potential to scale up quality newborn care by facilitating adherence to national guidelines.

31 August 2021 in JMIR Formative Research
Verified
Journal Article
Open access
PSParya Saberi
Parya Saberi
NLNadra Lisha
Nadra Lisha
XEXavier A Erguera
Xavier A Erguera
EHEstie Sid Hudes
Estie Sid Hudes
MJMallory O Johnson
Mallory O Johnson
Torsten B. NeilandsTorsten B. Neilands
Torsten B. Neilands
Background: Youth are globally recognized as being vulnerable to HIV. Younger age has been correlated with worse health outcomes. Mobile health (mHealth) interventions have the potential to interact with youth where they are, using a device they already access. Objective: Using predefined benchmarks, we sought to evaluate the feasibility and acceptability of WYZ, an mHealth app, for improved engagement in care and antiretroviral therapy (ART) adherence among youth and young adults living with HIV. WYZ was designed and developed with input from youth and young adults living with HIV using a human-centered design approach and was based on the information, motivation, and behavioral skills framework to address common barriers to care and ART adherence among youth and young adults living with HIV. Methods: We recruited youth and young adults living with HIV (18-29 years old) from the San Francisco Bay Area to take part in a 6-month pilot trial. Their participation included completing baseline and exit surveys, and participating in seven phone check-ins about their use of WYZ. Results: Youth and young adults living with HIV (N=79) reported high levels of feasibility and acceptability with WYZ use. We met predefined benchmarks for recruitment (79/84, 94%), mean logins per week (5.3), tracking ART adherence (5442/9393, 57.9%), posting chat topics per week (4.8), and app crashes reported per week (0.24). The ease of app download, install, and setup, and comfort with security, privacy, and anonymity were highly rated (all over 91%). Additionally, participants reported high satisfaction for a research project that was remotely conducted. Participants used the app for shorter timeframes compared to the predefined benchmark. Conclusions: We noted high feasibility and acceptability with WYZ. Further research to examine the efficacy of WYZ will enable youth and young adults living with HIV and their providers to make informed decisions when using, recommending, and prescribing the app for improved engagement in HIV care and ART adherence. Trial Registration: ClinicalTrials.gov NCT03587857; https://clinicaltrials.gov/ct2/show/NCT03587857

1 March 2021 in The Lancet HIV
Verified
Journal Article
Closed access
TRTheodore D Dumont Ruel
Theodore D Dumont Ruel
ECEdmund V Capparelli
Edmund V Capparelli
CTCamlin Tierney
Camlin Tierney
BNBryan S Nelson
Bryan S Nelson
ACAnne Coletti
Anne Coletti
ECEllen G Chadwick
Ellen G Chadwick